


- ferentiate into hematopoietic and cobblestone area-supporting cells. *Exp. Hematol.* 31:715-722.
27. Kocisko, D. A., W. S. Caughey, R. E. Race, G. Roper, B. Caughey, and J. D. Morrey. 2006. A porphyrin increases survival time of mice after intracerebral prion infection. *Antimicrob. Agents Chemother.* 50:759-761.
 28. Lee, P. H., J. W. Kim, O. Y. Bang, Y. H. Ahn, I. S. Joo, and K. Huh. 2008. Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy. *Clin. Pharmacol. Ther.* 83:723-730.
 29. Li, Y., J. Chen, X. G. Chen, L. Wang, S. C. Gautam, Y. X. Xu, M. Katakowski, L. J. Zhang, M. Lu, N. Janakiraman, and M. Chopp. 2002. Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery. *Neurology* 59:514-523.
 30. Li, Y., J. Chen, L. Wang, L. Zhang, M. Lu, and M. Chopp. 2001. Intracerebral transplantation of bone marrow stromal cells in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. *Neurosci. Lett.* 316:67-70.
 31. Mahmood, A., D. Lu, and M. Chopp. 2004. Marrow stromal cell transplantation after traumatic brain injury promotes cellular proliferation within the brain. *Neurosurgery* 55:1185-1193.
 32. Mantovani, A., F. Bussolino, and E. Dejana. 1992. Cytokine regulation of endothelial cell function. *FASEB J.* 6:2591-2599.
 33. Mazzini, L., K. Mareschi, I. Ferrero, E. Vassallo, G. Oliveri, N. Nasuelli, G. D. Oggioni, L. Testa, and F. Fagioli. 2008. Stem cell treatment in amyotrophic lateral sclerosis. *J. Neurol. Sci.* 265:78-83.
 34. Meier, P., N. Genoud, M. Prinz, M. Maissen, T. Rüllicke, A. Zurbriggen, A. J. Raeber, and A. Aguzzi. 2003. Soluble dimeric prion protein binds PrP^{Sc} *in vivo* and antagonizes prion disease. *Cell* 113:49-60.
 35. Mimura, T., M. Dezawa, H. Kanno, and I. Yamamoto. 2005. Behavioral and histological evaluation of a focal cerebral infarction rat model transplanted with neurons induced from bone marrow stromal cells. *J. Neuropathol. Exp. Neurol.* 64:1108-1117.
 36. Munoz, J. R., B. R. Stoutenger, A. P. Robinson, J. L. Spees, and D. J. Prockop. 2005. Human stem/progenitor cells from bone marrow promote neurogenesis of endogenous neural stem cells in the hippocampus of mice. *Proc. Natl. Acad. Sci. USA* 102:18171-18176.
 37. Nakamura, K., Y. Ito, Y. Kawano, K. Kurozumi, M. Kobune, H. Tsuda, A. Bizen, O. Honmou, Y. Niitsu, and H. Hamada. 2004. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. *Gene Ther.* 11:1155-1164.
 38. Nomura, T., O. Honmou, K. Harada, K. Houkin, H. Hamada, and J. D. Kocsis. 2005. I.V. infusion of brain-derived neurotrophic factor gene-modified human mesenchymal stem cells protects against injury in a cerebral ischemia model in adult rat. *Neuroscience* 136:161-169.
 39. Paxinos, G., and K. B. J. Franklin. 2001. *The mouse brain in stereotaxic coordinates.* Academic Press, Inc., San Diego, CA.
 40. Perrier, V., K. Kaneko, J. Safar, J. Vergara, P. Tremblay, S. J. DeArmond, F. E. Cohen, S. B. Prusiner, and A. C. Wallace. 2002. Dominant-negative inhibition of prion replication in transgenic mice. *Proc. Natl. Acad. Sci. USA* 99:13079-13084.
 41. Pittenger, M. F., A. M. Mackay, S. C. Beck, R. K. Jaiswal, R. Douglas, J. D. Mosca, M. A. Moorman, D. W. Simonetti, S. Craig, and D. R. Marshak. 1999. Multilineage potential of adult human mesenchymal stem cells. *Science* 284:143-147.
 42. Priller, J., M. Prinz, M. Heikenwalder, N. Zeller, P. Schwarz, F. L. Heppner, and A. Aguzzi. 2006. Early and rapid engraftment of bone marrow-derived microglia in scrapie. *J. Neurosci.* 26:11753-11762.
 43. Priola, S. A., A. Raines, and W. S. Caughey. 2000. Porphyrin and phthalocyanine antiscurie compounds. *Science* 287:1503-1506.
 44. Prockop, D. J. 1997. Marrow stromal cells as stem cells for nonhematopoietic tissues. *Science* 276:71-74.
 45. Rainov, N. G., Y. Tsuboi, P. Krolak-Salmon, A. Vighetto, and K. Doh-Ura. 2007. Experimental treatments for human transmissible spongiform encephalopathies: is there a role for pentosan polysulfate? *Expert Opin. Biol. Ther.* 7:713-726.
 46. Rüster, B., S. Göttig, R. J. Ludwig, R. Bistrrian, S. Müller, E. Seifried, J. Gille, and R. Henschler. 2006. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. *Blood* 108:3938-3944.
 47. Ryan, J. M., F. P. Barry, J. M. Murphy, and B. P. Mahon. 2005. Mesenchymal stem cells avoid allogeneic rejection. *J. Inflamm.* 2:8.
 48. Sanchez-Ramos, J. R. 2002. Neural cells derived from adult bone marrow and umbilical cord blood. *J. Neurosci. Res.* 69:880-893.
 49. Schultz, J., A. Schwarz, S. Neidhold, M. Burwinkel, C. Riemer, D. Simon, M. Kopf, M. Otto, and M. Baier. 2004. Role of interleukin-1 in prion disease-associated astrocyte activation. *Am. J. Pathol.* 165:671-678.
 50. Schwarz, A., O. Krätke, M. Burwinkel, C. Riemer, J. Schultz, P. Henklein, T. Bamme, and M. Baier. 2003. Immunisation with a synthetic prion protein-derived peptide prolongs survival times of mice orally exposed to the scrapie agent. *Neurosci. Lett.* 350:187-189.
 51. Segers, V. F., I. Van Riet, L. J. Andries, K. Lemmens, M. J. Demolder, A. J. De Becker, M. M. Kockx, and G. W. De Keulenaer. 2006. Mesenchymal stem cell adhesion to cardiac microvascular endothelium: activators and mechanisms. *Am. J. Physiol. Heart Circ. Physiol.* 290:H1370-H1377.
 52. Sigurdsson, E. M., D. R. Brown, M. Daniels, R. J. Kascsak, R. Kascsak, R. Carp, H. C. Meeker, B. Frangione, and T. Wisniewski. 2002. Immunization delays the onset of prion disease in mice. *Am. J. Pathol.* 161:13-17.
 53. Song, C. H., H. Furuoka, C. L. Kim, M. Ogino, A. Suzuki, R. Hasebe, and M. Horiuchi. 2008. Effect of intraventricular infusion of anti-prion protein monoclonal antibodies on disease progression in prion-infected mice. *J. Gen. Virol.* 89:1533-1544.
 54. Terada, N., T. Hamazaki, M. Oka, M. Hoki, D. M. Mastalerz, Y. Nakano, E. M. Meyer, L. Morel, B. E. Petersen, and E. W. Scott. 2002. Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion. *Nature* 416:542-545.
 55. Trevitt, C. R., and J. Collinge. 2006. A systematic review of prion therapeutics in experimental models. *Brain* 129:2241-2265.
 56. Vorbrodt, A. W., D. H. Dohrogowska, M. Tarnawski, H. C. Meeker, and R. I. Carp. 1997. Immunocytochemical evaluation of blood-brain barrier to endogenous albumin in scrapie-infected mice. *Acta Neuropathol.* 93:341-348.
 57. Wang, L., Y. Li, J. Chen, S. C. Gautam, Z. Zhang, M. Lu, and M. Chopp. 2002. Ischemic cerebral tissue and MCP-1 enhance rat bone marrow stromal cell migration in interface culture. *Exp. Hematol.* 30:831-836.
 58. Wang, L., Y. Li, X. Chen, J. Chen, S. C. Gautam, Y. Xu, and M. Chopp. 2002. MCP-1, MIP-1, IL-8 and ischemic cerebral tissue enhance human bone marrow stromal cell migration in interface culture. *Hematology* 7:113-117.
 59. Wang, Y., Y. Deng, and G. Q. Zhou. 2008. SDF-1 α /CXCR4-mediated migration of systemically transplanted bone marrow stromal cells towards ischemic brain lesion in a rat model. *Brain Res.* 1195:104-112.
 60. Wislet-Gendebien, S., G. Hans, P. LePrince, J. M. Rigo, G. Moonen, and B. Rogister. 2005. Plasticity of cultured mesenchymal stem cells: switch from nestin-positive to excitable neuron-like phenotype. *Stem Cells* 23:392-402.
 61. Woodbury, D., E. J. Schwarz, D. J. Prockop, and I. B. Black. 2000. Adult rat and human bone marrow stromal cells differentiate into neurons. *J. Neurosci. Res.* 61:364-370.
 62. Wuertzer, C. A., M. A. Sullivan, X. Qiu, and H. J. Federoff. 2008. CNS delivery of vectored prion-specific single-chain antibodies delays disease onset. *Mol. Ther.* 16:481-486.
 63. Yamaguchi, S., H. Wakimoto, Y. Yoshida, Y. Kanegae, I. Saito, M. Aoyagi, K. Hirakawa, T. Amagasa, and H. Hamada. 1995. Enhancement of retrovirus-mediated gene transduction efficiency by transient overexpression of the amphotropic receptor, GLVR-2. *Nucleic Acids Res.* 23:2080-2081.
 64. Zappia, E., S. Casazza, E. Pedemonte, F. Benvenuto, I. Bonanni, E. Gerdoni, D. Giunti, A. Ceravolo, F. Cazzanti, F. Frassoni, G. Mancardi, and A. Uccelli. 2005. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. *Blood* 106:1755-1761.



Generation of monoclonal antibody that distinguishes PrP^{Sc} from PrP^C and neutralizes prion infectivity

Motohiro Horiuchi^{a,*}, Ayako Karino^b, Hidefumi Furuoka^c, Naotaka Ishiguro^d,
Kumiko Kimura^e, Morikazu Shinagawa^f

^a Laboratory of Prion Diseases, Graduate School of Veterinary Medicine, Hokkaido University, Kita-18, Nishi-9, Kita-ku, Sapporo, Hokkaido 060-0818, Japan

^b Department of Veterinary Public Health, Obihiro University of Agriculture and Veterinary Medicine, Inada-cho, Obihiro, Hokkaido 080-8555, Japan

^c Department of Pathological Science, Obihiro University of Agriculture and Veterinary Medicine, Inada-cho, Obihiro, Hokkaido 080-8555, Japan

^d Laboratory of Food and Environmental Hygiene, Faculty of Applied Biological Science, Gifu University, Yanagito, Gifu 501-1193, Japan

^e Bovine Pathology Unit, National Institute of Animal Health, Kannondai, Tsukuba, Ibaraki 305-0856, Japan

^f Prion Disease Research Center, National Institute of Animal Health, Kannondai, Tsukuba, Ibaraki 305-0856, Japan

ARTICLE INFO

Article history:

Received 21 April 2009

Returned to author for revision 2 June 2009

Accepted 18 August 2009

Available online 18 September 2009

Keywords:

Prion

Transmissible spongiform encephalopathy

Monoclonal antibody

Peptide phage display

Infectivity

ABSTRACT

To establish PrP^{Sc}-specific mAbs, we immunized *Prnp*^{-/-} mice with PrP^{Sc} purified from prion-infected mice. Using this approach, we obtained mAb 6H10, which reacted with PrP^{Sc} treated with proteinase K, but not with PrP^{Sc} pretreated with more than 3 M GdnHCl. In contrast, reactivity of pan-PrP mAbs increased with increasing concentrations of GdnHCl used for pretreatment of PrP^{Sc}. In histoblot analysis, mAb 6H10 showed a positive reaction on a non-denatured histoblot but reactivity was lower when the histoblot was pretreated by autoclaving. Epitope analysis suggested that the extreme C-terminus of PrP is likely to be part of the epitope for mAb 6H10. MAb 6H10 immunoprecipitated PrP^{Sc} from brains of mice, sheep, and cattle infected with prions. Furthermore, pretreatment of purified PrP^{Sc} with mAb 6H10 reduced the infectious titer more than 1 log. Taken together, these results suggest that mAb 6H10 recognizes a conformational epitope on PrP^{Sc} that is related to prion infectivity.

© 2009 Elsevier Inc. All rights reserved.

Introduction

Prion diseases are fatal neurodegenerative diseases which include scrapie in sheep and goats, bovine spongiform encephalopathy (BSE), and Creutzfeldt-Jakob diseases (CJD) in humans. A hallmark of the diseases is the accumulation of a pathogenic, abnormal isoform of prion protein, designated PrP^{Sc}, in the central nervous system of affected animals. PrP^{Sc} is generated from the host-encoded, cellular prion protein, PrP^C, by certain post-translational modification including conformational transformation (Prusiner et al., 1998). Although the two isoforms are encoded by the host gene, *PrP*, they differ from each other biochemically and biophysically. For example, PrP^C is soluble in non-ionic detergents and sensitive to protease treatment, whereas PrP^{Sc} is insoluble due to its propensity to form aggregates that are partially resistant to protease treatment (Oesch et al., 1985; Meyer et al., 1986). PrP^C has a high α -helix but low β -sheet content, whereas PrP^{Sc} has a higher β -sheet content (Caughey et al., 1991; Pan et al., 1993; Safar et al., 1993). However, PrP^{Sc} is comprised of PK-sensitive and PK-resistant PrP^{Sc}, such that PrP^{Sc} cannot be distinguished from PrP^C simply using protease treatment (Bessen and Marsh, 1994; Safar et al., 1998, 2005; Silveira et al., 2005).

To date, there have been a number of reports on the production of monoclonal and polyclonal antibodies against PrP molecules. Most of these are pan-PrP antibodies that recognize either linear or discontinuous epitopes on PrP^C and react with PrP^{Sc} pretreated with denaturant (Kasczak et al., 1987; Serban et al., 1990; Williamson et al., 1996; Peretz et al., 1997; Kim et al., 2004a). Because of the co-existence of PrP^C and PrP^{Sc}, and the propensity of PrP^{Sc} to form aggregates, removal of PrP^C by protease treatment and subsequent denaturation are prerequisites for specific detection of PrP^{Sc} by pan-PrP antibodies. However, the ability to analyze the properties of PrP^{Sc} using pan-PrP antibodies is limited, as the biological and biochemical properties of PrP^{Sc} are affected by protease treatment and denaturation.

Molecular probes that specifically react to PrP^{Sc} and distinguish PrP^{Sc} from PrP^C can be a powerful tool for analysis of the entity of PrP^{Sc}. For instance, PrP^C will be act as a molecular probe for PrP^{Sc}, as PrP^C binds to PrP^{Sc} (Horiuchi et al., 1999). A fusion protein comprised of PrP^C and the immunoglobulin Fc region and a genetically modified antibody possessing PrP^C segments have been demonstrated to bind to PrP^{Sc} possibly via the PrP^C segments (Meier et al., 2003; Moroncini et al., 2004). Moreover, plasminogen binds to PrP^{Sc} not to PrP^C; however, plasminogen will bind to other serum proteins and thus, selectivity of the binding is obscure (Fischer et al., 2000). In contrast to many reports of pan-PrP mAbs, only a few studies have reported anti-PrP^{Sc} antibodies that specifically discriminate PrP^{Sc} from PrP^C (Korth

* Corresponding author. Fax: +81 11 706 5293.

E-mail address: horichi@vetmed.hokudai.ac.jp (M. Horiuchi).

et al., 1997; Paramithiotis et al., 2003; Curin Serbec et al., 2004; Jones et al., 2009).

Availability of a panel of PrP^{Sc}-specific antibodies is indispensable for analysis of the biochemical properties of PrP^{Sc}. Thus, in order to obtain PrP^{Sc}-specific antibodies, we immunized PrP-ablated (*Prnp*^{-/-}) mice with PrP^{Sc} purified from prion-infected mouse brains. Prion infectivity is thought to be associated with PrP^{Sc} oligomers; thus, we used non-denatured, purified PrP^{Sc} as the immunogen. One of the mAbs, clone 6H10, showed interesting reactivity to PrP molecules; mAb 6H10 reacted with non-denatured PrP^{Sc} but not with recombinant mouse PrP (rMoPrP) or denatured PrP^{Sc} in an enzyme-linked immunosorbent assay. This pattern of reactivity implied that mAb 6H10 recognizes PrP^{Sc} but not PrP^C, allowing for detailed characterization of mAb 6H10.

Results

Reactivity of mAb 6H10 to purified PrP^{Sc}

To obtain PrP^{Sc}-specific mAbs, we immunized *Prnp*^{-/-} mice with a purified PrP^{Sc} fraction and hybridoma supernatants were screened with the purified PrP^{Sc} and rMoPrP by enzyme-linked immunosorbent assay (ELISA). We established one mAb, 6H10 (isotype: IgG2b), which reacted with purified PrP^{Sc} but not with rMoPrP or PrP^{Sc} denatured with 6 M GdnHCl. This pattern of reactivity suggests that mAb 6H10 might specifically recognize the PrP^{Sc} conformation and thus, we further analyzed mAb 6H10.

Figure 1 shows reactivity of mAb 6H10 and pan-PrP mAbs to purified PrP^{Sc}. The mAbs 31C6, 44B1, and 72, which were characterized as pan-PrP mAbs, reacted with purified PrP^{Sc} before proteinase K (PK) treatment (0 µg/ml), but reactivity disappeared when PrP^{Sc} was pretreated with 20 µg/ml or higher concentrations of PK (Fig. 1a). It is known that PrP^{Sc} forms sedimentable aggregates, and PrP^C or protease-sensitive PrP molecules, which are expected to expose the epitopes for pan-PrP mAbs, are usually co-purified with PrP^{Sc} during purification. Thus, the drastic decline in reactivity of pan-PrP mAbs with increases in PK concentration is probably due to removal of protease-sensitive PrP species from the purified PrP^{Sc} fraction. In contrast to the results of pan-PrP mAbs, mAb 6H10 reacted with PrP^{Sc} treated with up to 320 µg/ml of PK (Fig. 1a).

Most of epitopes for pan-PrP mAbs are buried in aggregates of purified PrP^{Sc}, and become exposed as denaturation reveals cryptic epitopes (Kim et al., 2004a). In contrast, PrP^{Sc}-specific conformational epitope(s), if they exist, would be expected to be destroyed upon denaturation. Consistent with this, reactivity of mAb 6H10 gradually decreased and disappeared when PK-treated PrP^{Sc} was treated with more than 3 M GdnHCl (Fig. 1b). This is different from pan-PrP mAbs, which did not react with PK-treated PrP^{Sc} without denaturation (at 0 M GdnHCl) but reactivity became apparent and increased as the GdnHCl concentration is increased (Fig. 1b). Taken together, the results suggested that mAb 6H10 recognizes a conformational epitope on PrP^{Sc}. Consistent with this, mAb 6H10 did not react with PrP^{Sc} in immunoblot analysis (Fig. 2a). To confirm reactivity of mAb 6H10 to PrP^{Sc}, we performed immunoprecipitation analysis. The mAb 6H10 precipitated PrP^{Sc} into the bead-bound fraction from a suspension of a purified PrP^{Sc} fraction, whereas most of PrP^{Sc} remained in the unbound fraction in the case of mAb 31C6 or a negative control mAb (Fig. 2b). Following immunoprecipitation of PrP^{Sc} by mAb 6H10, the amount of PrP^{Sc} that remained in the corresponding supernatant was decreased.

Immunoprecipitation of PrP^{Sc} from brain homogenates by mAb 6H10

Next we performed immunoprecipitation from brain homogenates. The mAb 31C6 immunoprecipitated bands corresponding to PrP^C from brain homogenates of uninfected mouse, whereas mAb




Fig. 1. Reactivity of mAb 6H10 to PrP^{Sc} in ELISA. (a) Reactivity to PK-treated PrP^{Sc}. Wells were coated with 200 ng/well of purified, PK-untreated PrP^{Sc} of the Obihiro strain. After adsorption, wells were treated with the indicated concentrations of PK. After terminating PK activity with Pefabloc, the wells were subjected to the antibody reaction. The anti-PrP mAbs used were 6H10, 31C6, 72, and 44B1. Anti-KLH mAb was used as a negative control mAb. (b) Effect of denaturation of PrP^{Sc}. Purified PrP^{Sc} adsorbed to the wells was digested with 20 µg/ml PK and treated with GdnHCl (0–6 M) at r.t. for 1 h. Then wells were subjected to the antibody reaction.

6H10 did not. PrP precipitated from brain homogenates of mice infected with the Obihiro or Chandler strain by mAb 31C6 disappeared after PK treatment. In contrast, 6–7 kDa smaller PrP bands were detected when fractions immunoprecipitated from brain




Fig. 2. Reactivity of mAb 6H10 to PrP^{Sc} in Immunoblotting. (a) Reactivity of mAbs 6H10 and 31C6 on an immunoblot. PK-treated (+) and PK-untreated (-) brain homogenates of mice infected with the Obihiro strain were subjected to immunoblotting. (b) Immunoprecipitation. PK-digested purified PrP^{Sc} of the Obihiro strain in PBS containing 1% Triton X-100 was incubated with antibodies as indicated at the top. The antigen-antibody complexes were collected with magnetic beads coated with protein G. PrP^{Sc} in precipitates (ppt) and supernatants (sup) were detected by immunoblotting using HRP-conjugated mAb 31C6. Anti-KLH mAb (KLH) was used as a negative control mAb. PK-digested PrP^{Sc} fractions at 50 and 20 µg brain equivalents were loaded as controls.




Fig. 3. Immunoprecipitation of PrP^{Sc} by mAb 6H10. Brain homogenates (2.5%) of prion-infected or uninfected animals were incubated with 10 μ g of mAbs (6H10, 31C6, P2-168) and then immunoprecipitated with protein G coupled magnetic beads. Bead-bound fractions were treated with PK [PK (+)] or not [PK (-)] and then subjected to immunoblotting. The blots were probed with HRP-conjugated mAb 31C6. mAb P2-168 was used as a negative control mAb. Homo, brain homogenates of uninfected mice or mice infected with prions.

homogenates of the Obihiro or Chandler strain-infected mice with mAb 6H10 were treated with PK (Fig. 3). Thus, at least, some fraction of the PrP immunoprecipitated with mAb 6H10 was resistant to PK treatment. These results suggest that mAb 6H10 selectively recognizes an epitope specific to PrP^{Sc} and thus has a potential to distinguish PrP^{Sc} from PrP^C. Moreover, mAb 6H10 exhibited broad host specificity; the mAb reacted with PrP^{Sc} in the brains of scrapie-affected sheep and BSE-affected cattle (Fig. 3). These results suggest that, if not all, at least a certain population of PrP^{Sc} in the brains of prion-infected animals possesses the epitope for mAb 6H10 on its surface.

Recently, Biasini et al. (2008) reported that mAb 15B3, which is purported to be specific to PrP^{Sc} (Korth et al., 1997), also reacted with non-infectious PrP aggregates. Thus we analyzed reactivity of mAb 6H10 to PrP aggregates prepared from rMoPrP89-231 purified from *Escherichia coli* (Fig. 4). The mAb 31C6 immunoprecipitated both non-aggregated and aggregated rMoPrP89-231. In contrast, mAb 6H10 did not immunoprecipitate non-aggregated rMoPrP89-231, but showed weak reaction to aggregated rMoPrP89-231 at the same level as an isotype-matched negative control (mAb P2-168). Thus, the reaction of mAb 6H10 to aggregated rMoPrP89-231 appears to be a non-specific reaction that is possibly caused by a hydrophobic property of aggregated rMoPrP89-231. The same results were obtained when rMoPrP23-231 was used (data not shown). Considering that mAb P2-168 did not immunoprecipitate PrP^{Sc} from brains of prion-infected animals, again, the reactivity of mAb 6H10 to PrP^{Sc} in immunoprecipitation is thought to be a specific reaction between mAb 6H10 and the epitope on PrP^{Sc}.

Reactivity of mAb 6H10 to prion-infected and uninfected brain in histoblot

To further analyze the reactivity of mAb 6H10 to PrP^{Sc}, we performed histoblot analysis (Fig. 5a). Two pan-PrP antibodies, one of which is antiserum of *Prnp*^{-/-} mice immunized with rMoPrP (NIAH), and the other is mAb 110, showed positive reaction to histoblot of prion-infected and uninfected mouse brains. However, the positive signals nearly disappeared when the blots were pretreated with PK, indicating that the signals represented protease-sensitive PrP. When the PK-treated histoblots were further processed by autoclaving, which partially denatures PrP^{Sc} and thus exposes cryptic epitopes, these antibodies reacted only with prion-infected mouse brains. In contrast, mAb 6H10 reacted intensely to a histoblot of prion-infected

mouse brain pretreated with PK and the intensity was drastically reduced by autoclaving of the histoblot. These results indicated that PrP^{Sc} accumulated in the brain possessed the epitope for mAb 6H10. Unexpectedly, mAb 6H10 showed weak reaction to PK-untreated, uninfected mouse brain sample, although the reaction was not observed on a PK-treated histoblot. To examine whether mAb 6H10 reacts not only with PrP^{Sc} but also PrP^C in a histoblot, we used brains of wild-type (*Prnp*^{+/+}) and *Prnp*^{-/-} mice. The mAb 44B1, classified as pan-PrP mAb, reacted only with the brain of *Prnp*^{+/+} mice as expected. However, mAb 6H10 reacted weakly with both *Prnp*^{+/+} and *Prnp*^{-/-} mice brains (Fig. 5b). Thus, the weak reaction of mAb 6H10 to the brains of uninfected mice may be the result of the presence of a host antigen(s) other than PrP^C that shares an epitope similar to that for mAb 6H10.




Fig. 4. Reactivity of mAb 6H10 to non-infectious PrP aggregates. (a) Immunoprecipitation of non-aggregated rMoPrP89-231 (S) and aggregated rMoPrP89-231 (P) with mAbs 31C6, 6H10, and P2-168. The mAb P2-168 is an isotype-matched negative control for mAb 6H10. Samples were prepared as described in Materials and Methods, and 10 μ l of bead-bound fraction was loaded in each lane. The blot was probed with HRP-conjugated mAb 44B1. (b) After chemiluminescence reaction, the same blot in (a) was washed with PBST and re-probed with HRP-conjugated goat anti-mouse Igs (GE Healthcare) to ensure comparable amount of mAbs were used for each immunoprecipitation. Closed and open arrowhead indicate immunoglobulin heavy and light chain, respectively. Arrow indicates rMoPrP89-231 detected in the re-probing process.




Fig. 5. Histoblot analysis. (a) Cryosections of Obihiro strain-infected (Inf) and uninfected mice brains (Uninf) were blotted onto PVDF membranes. The histoblots on the 1st row were neither treated with autoclave (AC-) nor PK (PK-). The blots on the 2nd row were treated with 50 μ g/ml PK (PK+) but not with autoclave (AC-), and those on the 3rd row were treated with PK (PK+) and then autoclaved (AC+). Antibodies: KLH, negative control mAb; NIAH, serum of *Prnp*^{-/-} mouse immunized with rMoPrP; 110, mAb 110; 6H10, mAb 6H10. (b) Histoblots of wild-type (*Prnp*^{+/+}) and *Prnp*^{-/-} mouse brains were stained with antibodies as indicated.

Neutralization of prion infectivity by mAb 6H10

Next, we examined whether mAb 6H10 can neutralize prion infectivity. Purified PrP^{Sc} from mice infected with the Obihiro strain was pre-incubated with mAbs and then inoculated intracerebrally to mice for a bioassay (Table 1). Pre-incubation of PrP^{Sc} with mAb 6H10 prolonged the mean incubation time by 19 days compared to PrP^{Sc}

Table 1
Neutralization of prion infectivity by mAb 6H10.

mAb	Numbers of mice		Incubation time to terminal stage [mean \pm SD (days)]
	Inoculated	PrP ^{Sc} positive	
Anti-KLH	5	5	161 \pm 4
mAb 31C6	5	5	166 \pm 6
mAb 110	5	5	169 \pm 7
mAb 6H10	5	5	180 \pm 8 ^a
Brain homogenate^b			
10%	10	10	161 \pm 6
1%	12	12	164 \pm 6
0.1%	12	12	175 \pm 6
0.01%	11	11	189 \pm 18
0.001%	12	12	212 \pm 12
0.0001%	11	11	245 \pm 31
0.00001%	6	3	278 \pm 52
0.000001%	6	0	>393

^a $p < 0.01$ by ANOVA followed by Dunnett's *post hoc* test.

^b To obtain an infectivity-incubation time standard curve, 10-fold serial dilutions of brain homogenates of mice infected with the Obihiro strain were bioassayed. The 50% lethal dose (LD₅₀) of the original homogenates (10% brain homogenates) was estimated to be 10⁶ LD₅₀/20 μ l by the Reed-Muench method. The standard curve for incubation periods (x) shorter than 190 days was fitted by the approximation of $LD_{50} = e^{41.48 - 0.183x}$. The standard curve for incubation periods (x) longer than 190 days was fitted by the approximation of $LD_{50} = e^{21.07 - 0.076x}$.

pretreated with negative control mAbs anti-KLH ($p < 0.01$), whereas pre-treatment with mAb 31C6 or 110 appeared to prolong the incubation time a little but the differences were not significant. A prolongation of 19 days was inferred as corresponding to a more than 95% reduction in prion infectivity based on the infectivity-incubation time standard curve obtained from bioassays of serially diluted brain homogenates from the Obihiro strain-infected mice (Table 1). Several pan-PrP mAbs have been reported to inhibit the accumulation of PrP^{Sc} in prion persistently infected neuroblastoma cells when the cells were incubated with those mAbs (Enari et al., 2001; Peretz et al., 2001; Perrier et al., 2004; Kim et al., 2004b). Cells persistently infected with the Obihiro strain were unavailable so far, we used mouse neuroblastoma cells persistently infected with the Chandler strain (I3/I5-9 cells, Kim et al., 2004b) to examine whether mAb 6H10 inhibits PrP^{Sc} formation in cells. Cells were cultured with mAb 6H10 (up to 20 μ g/ml) for 4 days; however, mAb 6H10 did not affect the PrP^{Sc} formation in I3/I5-9 (data not shown). Our previous study showed that anti-PrP mAbs strongly reacted with PrP^C on the cell surface could inhibit PrP^{Sc} formation in I3/I5-9 cells (Kim et al., 2004b). However, mAb 6H10 did not react with cell surface of I3/I5-9 cells by flowcytometric analysis (data not shown).

Epitope for mAb 6H10

To investigate the epitope for mAb 6H10, we adopted phage display analysis. Fig. 5a shows consensus amino acid (aa) residues deduced from selected phage clones with mAbs 31C6 or 110, or rabbit polyclonal antibodies (pAb) B103. Three or four aa residues of the phage clones selected with mAbs 31C6 and 110 were identical to the aa residues in regions determined by pepspots analysis (Kim et al., 2004a). Similarly, three or four aa residues of selected phage clones with pAb B103 were identical to the synthetic peptide used as the immunogen. These results suggest that at least three residues are required to form an epitope for antibody. In total, 56 phage clones selected after five rounds of panning with mAb 6H10, and these were subjected to DNA sequencing so that the aa sequences could be deduced. The consensus aa residues of two abundant phage clones are listed in Fig. 6a. The most abundant phage clone ph#121 contained four residues identical to the C-terminus of MoPrP (SPSQAWLYMRHE, underlined residues). The second most abundant phage clone ph#125 also had three residues identical to the C-terminus of MoPrP (TQNWSMSMLLKQ, underlined residues). In contrast, no aa sequence identity to MoPrP was observed in the third most abundant phage clone ph#98 (IPLTGKYLDEQS, 6/56, 11%). Binding of antibodies to selected phage clones was confirmed by captured ELISA (Fig. 6b). The mAb 6H10 reacted with phage clones ph#121 and ph#125, originally selected by mAb 6H10, but not with ph#6, originally selected by mAb 31C6. On the other hand, mAb 31C6 reacted only with phage clone ph#6. Taken together, these data demonstrate the specificity of phage clone selection. Moreover, the results suggest that the C-terminus of MoPrP is involved in the formation of the epitope for mAb 6H10. We also analyzed the epitope for mAb 6H10 using a pepspots membrane; however, mAb 6H10 did not react with any spots (data not shown).

Discussion

Immunization of *Prnp*^{-/-} mice and screening of hybridomas with non-denatured PrP^{Sc} is one of the ways to establish PrP^{Sc}-specific mAbs. Using this approach, we obtained mAb 6H10, which reacted with non-denatured PrP^{Sc} but not with denatured PrP^{Sc}. It is well known that epitopes for pan-PrP antibodies on PrP^{Sc} become accessible by antibodies after dissociation of PrP^{Sc} aggregates and/or denaturation of PrP^{Sc} (Kascsak et al., 1987; Serban et al., 1990; Williamson et al., 1996). However, the reactivity of mAb 6H10 to PrP^{Sc} decreased with the increases in GdnHCl concentration for the pretreatment of PrP^{Sc} to 3 M, indicating that the properties of mAb

a

Antibody: mAb 31C6	
aa sequence of epitope	143-DWEDRYRE-231
Deduced aa sequences	DxxxRxxxE (6/11) DWxxR (2/11)
Possible epitope	<u>DWEDRYRE</u>
Antibody: mAb 110	
aa sequence of epitope	83-PHGGGWG-89
Deduced aa sequences	PxGxGW (6/10) PxGxxW (1/10)
Possible epitope	<u>PHGGGWG</u>
Antibody: pAb B103	
aa sequence of epitope	90-QGGTHGQWNKPSKPKTNMK-109
Deduced aa sequences	NKxxxP (7/11) HxxxNKxxxP (2/11)
Possible epitope	<u>QGGTHGQWNKPSKPKTNMK</u>
Antibody: mAb 6H10	
aa sequence of epitope	NA
Deduced aa sequences	SQAxxxxR (24/56) TQxxxxS (13/56)
Possible epitope	213-CVT <u>TQYQKESQA</u> YYDGRSS-231

b




Fig. 6. Epitope analysis by peptide phage display. (a) Identity of aa sequences between selected phage clones and the region to which antibodies are expected to bind. The aa sequence of the epitopes of mAbs 110 and 31C6 were determined by pepspots analysis (Kim et al., 2004a), whereas that of pAb B103 corresponds the synthetic peptide used for immunization (Horiuchi et al., 1995). The deduced aa sequences indicate that consensus aa residues of selected phage clones. Shown are two abundant consensus sequences deduced from selected phage clones, which were obtained after three rounds (for pAb B103, and mAbs 110 and 31C6) or five rounds (for mAb 6H10) of panning. Amino acid residues identical to the expected region are indicated in bold. Numbers in parentheses indicate the total number of phage clones analyzed for each antibody (denominators) and the numbers of phage clones that possess the corresponding consensus aa sequence (numerators). The residues that are expected to constitute the epitope for each antibody are underlined (possible epitope). (b) Binding of antibodies to selected phage clones. Wells coated with mAb 6H10 or 31C6 were incubated with four-fold serial dilutions of the selected phage clones (ph#121, ph#125, or ph#6). Phage-antibody complexes were detected as described in Materials and Methods. Phage clones ph#121 and ph#125, selected by mAb 6H10, express the peptides SPSQAWLYMRHE and TQNWSMSMLLKQ, respectively. Phage ph#6, selected by mAb 31C6, expresses peptide SDWHTRFHYSMN (underlining indicates the consensus aa residues for the corresponding epitope).

6H10 differ from those of pan-PrP mAbs. The infectivity of the Obihiro strain, which was used as a source of PrP^{Sc} in this study, was dramatically reduced by the treatment with 3 M GdnHCl (Shindoh et al., 2009), consistent with a decrease in the reactivity of mAb 6H10 to PrP^{Sc} of the Obihiro strain pretreated with 3 M GdnHCl. Furthermore, mAb 6H10 neutralized infectivity of PrP^{Sc} purified from mice infected with the Obihiro strain (Table 1). Thus, mAb 6H10 may recognize a conformational epitope on non-denatured PrP^{Sc} that is related to the oligomerization interface on the PrP^{Sc} molecule. Reduction of the hydrophobic surface on PrP^{Sc} correlated with the dissociation and/or denaturation of PrP^{Sc} by GdnHCl at concentrations between 0 and 3 M (Safar et al., 1994). Circular dichroism analysis also revealed that GdnHCl dissociated PrP^{Sc} aggregates with a midpoint of transition around 2 M (Safar et al., 1993). The half-maximal GdnHCl concentrations, which are required to denature 50% of PrP^{Sc}, have been reported to range from 1.5 to 3 M for most of mouse-adapted scrapie and BSE prions (Legname et al., 2006; Shindoh et al., 2009). In addition, treatment of samples with 2–4 M GdnHCl resulted in decrease of prion infectivity (Caughey et al., 1997; McKenzie et al., 1998). Although these reports used different prion strains, the decrease in reactivity of mAb 6H10 to PrP^{Sc} with an increase in GdnHCl concentration for pretreatment of PrP^{Sc} concurs with structural alteration of PrP^{Sc} or the decrease of infectivity induced by GdnHCl at similar concentrations.

The results of phage display analysis suggested the possibility that the extreme C-terminus of PrP molecule is part of the epitope for mAb 6H10. Among the amino acid residues expected to compose the epitope for mAb 6H10 (aa215-TQxxxxSQAxxxxR-aa228 of MoPrP), the underlined residues are identical to those of sheep and bovine PrP. This may be consistent with the fact that mAb 6H10 could immunoprecipitate PrP^{Sc} from sheep and cattle samples. The mAb

6H10 showed no reaction with denatured PrP^{Sc} by immunoblotting or ELISA (Figs. 1 and 2), or with the corresponding C-terminal peptide by pepspots analysis (data not shown). In contrast, reactivity of mAbs that recognize linear epitopes on the extreme C-terminus increased after pretreatment of PrP^{Sc} with denaturants (Peretz et al., 1997; Kim et al., 2004a). Thus it is unlikely that mAb 6H10 binds linear epitope composed of the C-terminal residues. One mAb, V5B2, which was raised against a synthetic peptide corresponding to the C-terminal residues of human PrP (aa214-CITQYERESQAYY-aa226), is reported to discriminate PrP^{Sc} in brains of CJD patients from PrP^C in non-CJD brains possibly by recognizing the oligomerized C-terminal region in PrP^{Sc} oligomers (Curin Serbec et al., 2004; Ulrih et al., 2006). Therefore, the C-terminal regions of two PrP molecules may cooperate to form a conformational epitope; however, the exact properties of the epitope for 6H10 are not yet fully elucidated. Alternatively, in the proposed model of PrP^{Sc} protofibrils, the C-terminal region is thought to be located in close proximity to other regions on the same or different PrP molecule (DeMarco and Daggett, 2004; Govaerts et al., 2004). Cross-linking of recombinant PrP oligomers revealed that an interaction between the N- and C-terminal regions (Kaimann et al., 2008). Thus, the C-terminal region and other regions on the same or different PrP molecule may participate in constituting the epitope for mAb 6H10. The mAb 15B3, which was produced by immunizing recombinant bovine PrP and is purported to be specific to PrP^{Sc}, reacted with three PrP segments, residues 141–147, 161–269, and 213–215 of MoPrP in pepspots analysis (Korth et al., 1997). Involvement of the extreme C-terminus in the epitope for mAb 15B3 is intriguing; however, mAb 6H10 did not react with any PrP peptides in pepspots analysis (data not shown). Thus, the epitope for mAb 6H10 seems to differ from that for mAb 15B3. Recently, mAb 15B3 is reported to react with infectious and non-infectious PrP

aggregates (Biasini et al., 2008), therefore, we analyzed the reactivity of mAb 6H10 to aggregated rMoPrP (Fig. 4). Although a weak non-specific reaction to aggregated rMoPrP was observed, mAb 6H10 did not show any specific reaction to aggregated rMoPrP, suggesting mAb 6H10 is more specific to PrP^{Sc} generated in brains of prion-infected animals.

Some mAbs against either PrP or non-PrP molecules have been reported to immunoprecipitate PrP^{Sc} via an epitope-independent reaction when mAbs were bound to a solid phase such as magnetic beads, as binding of immunoglobulins on the limited area of the solid surface increases the concentration of immunoglobulins in that area and thus a low-affinity interaction between PrP^{Sc} and immunoglobulins on the beads may occur (Morel et al., 2004). We considered that this possibility is unlikely in the case of mAb 6H10 for several reasons. First, bead-free mAb 6H10 reacted with PrP^{Sc} in ELISA and histoblot analysis (Figs. 1 and 5). In addition, a direct interaction of fluorescent dye-labeled mAb 6H10 with non-denatured PrP^{Sc} in brain homogenates of mice infected with prions can be detected in solution by fluorescent correlation spectroscopy (K. S. and M.H., in preparation). Secondly, a Fab' fragment of mAb 6H10 still reacted with native purified PrP^{Sc} in ELISA (data not shown). However, a weak non-specific reaction to aggregated rMoPrP would be expected depending on experimental conditions (Fig. 4), careful experimental design, such as the use of negative control mAb and comparison between prion-infected and mock-infected materials, will be required to ensure specific reactivity of mAb 6H10 to PrP^{Sc}.

The reactivity of mAb 6H10 to PrP^{Sc} in biochemical analysis strongly suggests that mAb 6H10 discriminates PrP^{Sc} from PrP^C. However, in histoblot analysis, the mAb showed weak reaction to certain host molecule in *Prnp*^{-/-} mice. This raises two possibilities. First, the mAb may recognize a host molecule other than PrP with an epitope similar to that for mAb 6H10 on PrP^{Sc}. The presence of third abundant phage clone (ph#98) that selected by mAb 6H10, aa sequence of which showed no apparent homology to PrP, may clue the identification of such host molecule. However, no protein or peptide domain was found by homology search using protein blast and tblastn or domain search using Conserved Domain Database. Secondly, the mAb may recognize a host factor tightly associated with PrP^{Sc} in the prion-infected mouse brain, rather than reacting with PrP^{Sc} itself. The latter possibility suggests that the positive reaction to PK-treated PrP^{Sc} in ELISA was due to a reaction to a PK-resistant molecule tightly associated with PrP^{Sc}, which seems unlikely because the PrP^{Sc} fraction used in this study was estimated to be nearly 90% pure after PK treatment (Kim et al., 2004a). However, this possibility cannot be completely ruled out at present, particularly as several macromolecules, including glycosaminoglycans (Snow et al., 1989), ubiquitin (Lowe et al., 1990), apolipoprotein E (Namba et al., 1991) have been shown to co-localize with PrP^{Sc} in brains of prion-infected animals and human. In addition, nucleic acids (Aiken et al., 1990; Sklaviadis et al., 1993) and sphingolipid (Klein et al., 1998) have been co-purified with PrP^{Sc}.

In this study, we showed the possibility that the C-terminal region forms a PrP^{Sc}-specific epitope. Recently, immunization of β -form recombinant human PrP could induce production of mAbs that react with the N-terminal region of PrP^{Sc} (aa91–110; Khalili-Shirazi et al., 2007). The immunization of aggregated synthetic peptide corresponding to aa106–126 of PrP also generated a mAb that discriminates PrP^{Sc} from PrP^C (Jones et al., 2009). These results suggest that PrP^{Sc}-specific epitopes are present at various regions on PrP^{Sc}. A fusion protein of PrP and Fc-region of immunoglobulin and PrP-peptide-grafted antibodies have been reported to recognize PrP^{Sc} (Meier et al., 2003; Moroncini et al., 2004, 2006; Solforosi et al., 2007; Lau et al., 2007). In addition, there are nucleotide aptamers that possess higher affinity to PrP^{Sc} than to PrP^C (Rhie et al., 2003), and small chemicals such as 9-aminoacridine, streptomycin, luminescent conjugated polymers, polyionic polymers Sepriion (Microsens bio-

technologies) and others, may also act as PrP^{Sc}-specific probes (Moussa et al., 2006; Phuan et al., 2007; Sigurdson et al., 2007). Despite technical difficulties in manipulating PrP^{Sc} due to its aggregation-prone propensity and heterogeneity, PrP^{Sc}-specific molecular probes are gradually accumulating. As the availability of a panel of anti-PrP mAbs has greatly contributed to characterization of the biochemical properties of PrP, a panel of PrP^{Sc}-specific molecular probes appears to be indispensable tools for analyzing the biochemical and biological properties of native PrP^{Sc} with which prion infectivity is believed to be associated.

Materials and methods

Purification of PrP^{Sc} and production of mAbs

The purification PrP^{Sc} from brains of mice infected with prion Obihiro strain and purity of PrP^{Sc} were reported elsewhere (Kim et al., 2004a). Immunization of PrP^{Sc} and production of mAbs were carried out as described (Kim et al., 2004a).

Antibodies

The following mAbs against mouse PrP molecules were used: 31C6 (IgG1, epitope: aa 143–149), 44B1 (IgG 2a, epitope: aa 155–231), 72 (IgG1, epitope: aa 89–231), and 110 (IgG2b, epitope: aa 59–89) (Kim et al., 2004a). Anti-keyhole limpet hemocyanin (KLH) mAb (IgG2a) and anti-parvovirus mAb P2-168 (IgG2b) (Horiuchi et al., 1997) were used as negative controls. Rabbit antiserum raised against bovine PrP synthetic peptide 103–121 (pAb B103) was also used (Horiuchi et al., 1995). Purification of mAbs was carried out as described elsewhere (Kim et al., 2004a). Conjugation of mAbs with horseradish peroxidase (HRP) was carried out as follows: purified mAbs were digested with pepsin and reduced by 2-mercapthoethanolamine (MEA) to generate Fab' fragments. After removal of MEA with a PD-10 size exclusion column (GE Healthcare), the Fab' fragments were mixed with HRP coupled with the bi-directional cross-linker GMBS (Dojin).

ELISA

Ninety-six well plates (MaxiSorp, Nunc) were coated overnight at 4 °C with either 200 ng purified PrP^{Sc} or 100 ng rMoPrP in 50 μ l of 20 mM phosphate buffer (pH 7.0). After adsorption, wells were blocked with 5% fetal bovine serum (FBS) in PBS containing 0.1% Tween 20 (PBST) for 2 h at room temperature (r.t.), and incubated with antibodies diluted with 1% FBS in PBST for 1 h. After washing with PBST, wells were incubated with HRP-conjugated secondary antibodies for 1 h. The antigen-antibody complexes were visualized with 2,2'-azino-bis(3-ethyl-benzthiazoline-6-sulfonic acid), 0.04% H₂O₂ in 50 mM citrate-phosphate buffer, pH 4.0, and the absorbance at 405 nm was measured with a microplate reader. In some cases, PrP^{Sc} adsorbed to the well was digested with various concentrations of proteinase K (PK) in Tris-buffered saline (TBS; 50 mM Tris-HCl [pH 8.0] and 150 mM NaCl) at 37 °C for 45 min. After terminating PK activity by adding Pefabloc (Roche Diagnostic) to a final concentration at 2 mM, the plates were subjected to the immune reaction.

Immunoblotting

SDS-PAGE and immunoblotting of proteins on an Immobilon-P Transfer Membrane (Millipore) were carried out as described elsewhere (Kim et al., 2004a, 2004b). Membranes were blocked with 5% skim milk in PBST for 1 h and then incubated with HRP-conjugated Fab fragment of anti-PrP mAbs (direct staining) or anti-PrP mAb followed by incubation with HRP-conjugated secondary antibodies (indirect staining). ECL Western blotting detection reagents (GE Healthcare) and X-ray film were used for visualization.

Immunoprecipitation

Protein G-coupled magnetic beads (Dynabeads) were blocked with blocking buffer containing 5% skim milk and 50% Sea Block (Pierce) in PBS. Brain homogenates (2.5%) from prion-infected or uninfected animals were prepared with PBS containing 0.5% I-Block (Applied Biosystem), and were incubated with 10 µg of mAb and protein G magnetic beads for 45 min at 37 °C. The magnetic beads were washed four times with PBS containing 2% Triton X-100 using a magnetic separator. After washing, the beads were suspended with 50 µl of TBS and divided into two tubes. An equal volume of 2 sample buffer (8 M urea, 10% SDS, 8% *b*-mercaptoethanol, 125 mM Tris-HCl [pH 6.8], 6 mM EDTA, 10% glycerol, and 0.04% bromophenol blue) was added to one tube to make samples without PK treatment. The other was treated with 40 µg/ml of PK for 30 min at 37 °C. The reaction with PK was stopped with 2 mM Pefabloc before adding 2 sample buffer.

To examine the reactivity of mAbs to non-infectious PrP aggregates, rMoPrP23-231 or rMoPrP89-231 (Kim et al., 2004a) were diluted to 20 µg/ml with 1 ml of 1% Triton-X 100 in PBS (PBS-Triton, pH 7.2) and kept for 30 min at 20 °C. Then samples were centrifuged at 100,000×*g* for 45 min at 20 °C. The supernatant was recovered and used as non-aggregated rMoPrP, while the resulting precipitate was resuspended with 1 ml of PBS-Triton by sonication and used as aggregated rMoPrP. Protein G-coupled magnetic beads (100 µl) were incubated with 20 µg of mAbs and then blocked with 5% skim milk and 5% N102 blocking reagent (NOF Corporation, Japan) in PBS-Triton for 1 h at r.t. After washing with PBS-Triton once, the beads were mixed with 300 µl of non-aggregated or aggregated rMoPrP for 45 min at r.t. The beads were washed four times with 1 ml of 2% Triton X-100 in PBS and finally washed with PBS. Proteins bound to the magnetic beads were eluted with 100 µl of 1× sample buffer.

Histoblot analysis

Histoblot analysis was carried out as described by Taraboulos et al. (1992). Immobilon-P Transfer Membranes were activated with methanol and then equilibrated with lysis buffer (0.5% Nonidet P-40, 0.5% sodium deoxycholate, 100 mM NaCl, 10 mM EDTA, 10 mM Tris-HCl [pH 7.8]). Mouse brain cryosections (8 µm) were prepared and placed on glass slides. The glass slides carrying the sections were immediately pressed onto membranes on layers of filter paper saturated with lysis buffer for 1 min. The membranes were thoroughly air-dried and stored at -80 °C until use. Before immunostaining, the membranes were rehydrated in PBST for 1 h at r.t. and then immunostaining was carried out as described above for immunoblotting.

Neutralization of prion infectivity

Fifteen micrograms of purified PrP^{Sc} were incubated with 36 µg of mAb in 300 µl of PBS containing 0.1% Zwittergent 3-12 for 2 h at r.t. The mixture (20 µl) containing 1 µg PrP^{Sc} was then inoculated intracerebrally into 4-week-old female slc:ICR mice. For dose-infectivity correlation, 20 µl each of serially diluted brain homogenates from mice infected with the Obihiro strain were inoculated intracerebrally to 4-week-old female slc:ICR mice.

Peptide phage display

The Ph.D.-12™ Phage Display Library Kit (New England Biolabs), a combinatorial library which expresses random 12-mer-peptides at the N-terminus of a minor coat protein of M13 phage, was used according to the supplier's instructions. Polystyrene Petri dishes (60×15 mm) were coated overnight at 4 °C with 1.5 ml of 100 µg/ml antibodies in 0.1 M NaHCO₃ (pH 8.6). After blocking with 0.5% FBS in PBS for 1 h, dishes were rinsed six times with PBST and then

inoculated with 4×10¹⁰ of the phage library. After 1 h incubation at r.t., the dishes were washed 10 times with PBS and then bound phage was eluted by addition of 1 ml 0.2 M glycine-HCl (pH 2.2) for 10 min. The eluate was immediately neutralized with 150 µl of 1 M Tris-HCl (pH 9.1). In total, 1 ml of the eluate was used for amplification of the selected phage pool and the amplified phage stock was subsequently used for the next panning.

After three to five rounds of panning, phage DNA encoding the selected random peptide sequences was amplified directly from individual plaques by PCR using primers PD12F (5'-TCAAGCTGTT-TAAGAAATTCACC-3') and PD12R (5'-TAAAGTTTTGTCGTCTTTCCAGAC-3'). The PCR products were purified by S-300 HR spin column (GE Healthcare) and used as templates for DNA sequencing. DNA sequences were determined with an automated DNA sequencer (ABI-373A, Applied Biosystems) and using the ABI PRISM Dye Terminator Cycle Sequencing Ready Reaction Kit.

Binding of antibodies to selected peptides was confirmed by a captured ELISA. Briefly, 96-well plates coated with antibodies (20 ng/well) were incubated with four-fold serial dilutions of the phage stock for 1 h at r.t. After washing with PBST, plates were incubated with HRP-conjugated anti-M13 antibody to detect the phage captured by the antibodies. Phage-antibody complexes were detected as described for ELISA.

Pepsin analysis

Pepsin analysis was carried out as described elsewhere (Kim et al., 2004a).

Statistical analysis

Statistical analysis was done with JMP software (SAS Institute Inc.).

Acknowledgments

This work was supported by a grant from the global COE Program (F-001) and a Grant-in-Aid for Science Research (A) (grant 18208026) and a Grant-in-Aid for Exploratory Research (grant 20658070) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan. This work was also supported by a grant from the Ministry of Health, Labour and Welfare of Japan (grant 20330701, Research on Measures for Intractable Diseases). This work was also partly supported by a grant-in-aid from the BSE Control Project of the Ministry of Agriculture, Forestry and Fisheries of Japan, a grant for Strategic Cooperation to Control Emerging and Re-emerging Infections, and the Program of Founding Research Centers for Emerging and Reemerging Infectious Diseases, from the Ministry of Education, Culture, Sports, Science, and Technology, Japan.

References

- Aiken, J.M., Williamson, J.L., Borchardt, L.M., Marsh, R.F., 1990. Presence of mitochondrial D-loop DNA in scrapie-infected brain preparations enriched for the prion protein. *J. Virol.* 64, 3265–3268.
- Bessen, R.A., Marsh, R.F., 1994. Distinct PrP properties suggest the molecular basis of strain variation in transmissible mink encephalopathy. *J. Virol.* 68, 7859–7868.
- Biasini, E., Seegulam, M.E., Patti, B.N., Solfrosi, L., Medrano, A.Z., Christensen, H.M., Senatore, A., Chiesa, R., Williamson, R.A., Harris, D.A., 2008. Non-infectious aggregates of the prion protein react with several PrP(Sc)-directed antibodies. *J. Neurochem.* 105, 2190–2204.
- Caughey, B.W., Dong, A., Bhat, K.S., Ernst, D., Hayes, S.F., Caughey, W.S., 1991. Secondary structure analysis of the scrapie-associated protein PrP 27-30 in water by infrared spectroscopy. *Biochemistry* 30, 7672–7680.
- Caughey, B., Raymond, G.J., Kocisko, D.A., Lansbury Jr., P.T., 1997. Scrapie infectivity correlates with converting activity, protease resistance, and aggregation of scrapie-associated prion protein in guanidine denaturation studies. *J. Virol.* 71, 4107–4110.
- Curin Serbec, V., Bresjanac, M., Popovic, M., Pretnar Hartman, K., Galvani, V., Ruprecht, R., Cernilec, M., Vranac, T., Hafner, I., Jerala, R., 2004. Monoclonal antibody against a peptide of human prion protein discriminates between Creutzfeldt-Jacob's disease-affected and normal brain tissue. *J. Biol. Chem.* 279, 3694–3698.

- DeMarco, M.L., Daggett, V., 2004. From conversion to aggregation: protofibril formation of the prion protein. *Proc. Natl. Acad. Sci. U.S.A.* 101, 2293–2298.
- Enari, M., Flechsig, E., Weissmann, C., 2001. Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. *Proc. Natl. Acad. Sci. U.S.A.* 98, 9295–9299.
- Fischer, M.B., Roeckl, C., Parizek, P., Schwarz, H.P., Aguzzi, A., 2000. Binding of disease-associated prion protein to plasminogen. *Nature* 408, 479–483.
- Govaerts, C., Wille, H., Prusiner, S.B., Cohen, F.E., 2004. Evidence for assembly of prions with left-handed beta-helices into trimers. *Proc. Natl. Acad. Sci. U.S.A.* 101, 8342–8347.
- Horiuchi, M., Yamazaki, N., Ikeda, T., Ishiguro, N., Shinagawa, M., 1995. A cellular form of prion protein (PrP^C) exists in many non-neuronal tissues of sheep. *J. Gen. Virol.* 76, 2583–2587.
- Horiuchi, M., Mochizuki, M., Ishiguro, N., Nagasawa, H., Shinagawa, M., 1997. Epitope mapping of a monoclonal antibody specific to feline panleukopenia virus and mink enteritis virus. *J. Vet. Med. Sci.* 59, 133–136.
- Horiuchi, M., Chabry, J., Caughey, B., 1999. Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease-resistant state. *EMBO J.* 18, 3193–3203.
- Jones, M., Wight, D., McLoughlin, V., Norrby, K., Ironside, J.W., Connolly, J.G., Farquhar, C.F., MacGregor, I.R., Head, M.W., 2009. An antibody to the aggregated synthetic prion protein peptide (PrP106–126) selectively recognizes disease-associated prion protein (PrP) from human brain specimens. *Brain Pathol.* 19, 293–302.
- Kaimann, T., Metzger, S., Kuhlmann, K., Brandt, B., Birkmann, E., Hölte, H.D., Riesner, D., 2008. Molecular model of an alpha-helical prion protein dimer and its monomeric subunits as derived from chemical cross-linking and molecular modeling calculations. *J. Mol. Biol.* 376, 582–596.
- Kascak, R.J., Rubenstein, R., Merz, P.A., Tonna-DeMasi, M., Fersko, R., Carp, R.I., Wisniewski, H.M., Diringer, H., 1987. Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins. *J. Virol.* 61, 3688–3693.
- Khalili-Shirazi, A., Kaisar, M., Mallinson, G., Jones, S., Bhelt, D., Fraser, C., Clarke, A.R., Hawke, S.H., Jackson, G.S., Collinge, J., 2007. Beta-PrP form of human prion protein stimulates production of monoclonal antibodies to epitope 91–110 that recognise native PrP^{Sc}. *Biochim. Biophys. Acta* 1774, 1438–1450.
- Kim, C.L., Umetani, A., Matsui, T., Ishiguro, N., Shinagawa, M., Horiuchi, M., 2004a. Antigenic characterization of an abnormal isoform of prion protein using a new diverse panel of monoclonal antibodies. *Virology* 320, 40–51.
- Kim, C.L., Karino, A., Ishiguro, N., Shinagawa, M., Sato, M., Horiuchi, M., 2004b. Cell-surface retention of PrP^C by anti-PrP antibody prevents protease-resistant PrP formation. *J. Gen. Virol.* 85, 3473–3482.
- Klein, T.R., Kirsch, D., Kaufmann, R., Riesner, D., 1998. Prion rods contain small amounts of two host sphingolipids as revealed by thin-layer chromatography and mass spectrometry. *Biol. Chem.* 379, 655–666.
- Korth, C., Stierli, B., Streit, P., Moser, M., Schaller, O., Fischer, R., Schulz-Schaeffer, W., Kretzschmar, H., Raeber, A., Braun, U., Ehrensperger, F., Hornemann, S., Glockshuber, R., Riek, R., Billeter, M., Wüthrich, K., Oesch, B., 1997. Prion (PrP^{Sc})-specific epitope defined by a monoclonal antibody. *Nature* 390, 74–77.
- Lau, A.L., Yam, A.Y., Michelitsch, M.M., Wang, X., Gao, C., Goodson, R.J., Shimizu, R., Timoteo, G., Hall, J., Medina-Selby, A., Coit, D., McCain, C., Phelps, B., Wu, P., Hu, C., Chien, D., Peretz, D., 2007. Characterization of prion protein (PrP)-derived peptides that discriminate full-length PrP^{Sc} from PrP^C. *Proc. Natl. Acad. Sci. U.S.A.* 104, 11551–11556.
- Legname, G., Nguyen, H.O., Peretz, D., Cohen, F.E., DeArmond, S.J., Prusiner, S.B., 2006. Continuum of prion protein structures enciphers a multitude of prion isolate-specified phenotypes. *Proc. Natl. Acad. Sci. U.S.A.* 103, 19105–19110.
- Lowe, J., McDermott, H., Kenward, N., Landon, M., Mayer, R.J., Bruce, M., McBride, P., Somerville, R.A., Hope, J., 1990. Ubiquitin conjugate immunoreactivity in the brains of scrapie infected mice. *J. Pathol.* 162, 61–66.
- McKenzie, D., Bartz, J., Mirwald, J., Olander, D., Marsh, R., Aiken, J., 1998. Reversibility of scrapie inactivation is enhanced by copper. *J. Biol. Chem.* 273, 25545–25547.
- Meier, P., Genoud, N., Prinz, M., Maissen, M., Rülcke, T., Zurbriggen, A., Raeber, A.J., Aguzzi, A., 2003. Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease. *Cell* 113, 49–60.
- Meyer, R.K., McKinley, M.P., Bowman, K.A., Braunfeld, M.B., Barry, R.A., Prusiner, S.B., 1986. Separation and properties of cellular and scrapie prion proteins. *Proc. Natl. Acad. Sci. U.S.A.* 83, 2310–2314.
- Morel, N., Simon, S., Frobert, Y., Volland, H., Mourton-Gilles, C., Negro, A., Sorgato, M.C., Créminon, C., Grassi, J., 2004. Selective and efficient immunoprecipitation of the disease-associated form of the prion protein can be mediated by nonspecific interactions between monoclonal antibodies and scrapie-associated fibrils. *J. Biol. Chem.* 279, 30143–30149.
- Moroncini, G., Kanu, N., Solfrosi, L., Abalos, G., Telling, G.C., Head, M., Ironside, J., Brockes, J.P., Burton, D.R., Williamson, R.A., 2004. Motif-grafted antibodies containing the replicative interface of cellular PrP are specific for PrP^{Sc}. *Proc. Natl. Acad. Sci. U.S.A.* 101, 10404–10409.
- Moroncini, G., Mangieri, M., Morbin, M., Mazzoleni, G., Ghetti, B., Gabrielli, A., Williamson, R.A., Giaccone, G., Tagliavini, F., 2006. Pathologic prion protein is specifically recognized in situ by a novel PrP conformational antibody. *Neurobiol. Dis.* 23, 717–724.
- Moussa, A., Coleman, A.W., Bencsik, A., Leclere, E., Perret, F., Martin, A., Perron, H., 2006. Use of streptomycin for precipitation and detection of proteinase K resistant prion protein (PrP^{Sc}) in biological samples. *Chem. Commun.* 9, 973–975.
- Namba, Y., Tomonaga, M., Kawasaki, H., Otomo, E., Ikeda, K., 1991. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. *Brain Res.* 541, 163–166.
- Oesch, B., Westaway, D., Wälchli, M., McKinley, M.P., Kent, S.B., Aebersold, R., Barry, R.A., Tempst, P., Teplow, D.B., Hood, L.E., Prusiner, S.B., Weissmann, C., 1985. A cellular gene encodes scrapie PrP 27–30 protein. *Cell* 40, 735–746.
- Pan, K.M., Baldwin, M., Nguyen, J., Gasset, M., Serban, A., Groth, D., Mehlhorn, I., Huang, Z., Fletterick, R.J., Cohen, F.E., Prusiner, S.B., 1993. Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. *Proc. Natl. Acad. Sci. U.S.A.* 90, 10962–10966.
- Paramithiotis, E., Pinard, M., Lawton, T., LaBoissiere, S., Leathers, V.L., Zou, W.Q., Estey, L.A., Lamontagne, J., Lehto, M.T., Kondejewski, L.H., Francoeur, G.P., Papadopoulos, M., Haghighat, A., Spatz, S.J., Head, M., Will, R., Ironside, J., O'Rourke, K., Tonelli, Q., Ledebur, H.C., Chakrabarty, A., Cashman, N.R., 2003. A prion protein epitope selective for the pathologically misfolded conformation. *Nat. Med.* 9, 893–899.
- Peretz, D., Williamson, R.A., Matsunaga, Y., Serban, H., Pinilla, C., Bastidas, R.B., Rozenshteyn, R., James, T.L., Houghten, R.A., Cohen, F.E., Prusiner, S.B., Burton, D.R., 1997. A conformational transition at the N terminus of the prion protein features in formation of the scrapie isoform. *J. Mol. Biol.* 273, 614–622.
- Peretz, D., Williamson, R.A., Kaneko, K., Vergara, J., Leclerc, E., Schmitt-Ulms, G., Mehlhorn, I.R., Legname, G., Wormald, M.R., Rudd, P.M., Dwek, R.A., Burton, D.R., Prusiner, S.B., 2001. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. *Nature* 412, 739–743.
- Perrier, V., Solassol, J., Crozet, C., Frobert, Y., Mourton-Gilles, C., Grassi, J., Lehmann, S., 2004. Anti-PrP antibodies block PrP^{Sc} replication in prion-infected cell cultures by accelerating PrP^C degradation. *J. Neurochem.* 89, 454–463.
- Phuan, P.W., Zorn, J.A., Safar, J., Giles, K., Prusiner, S.B., Cohen, F.E., May, B.C., 2007. Discriminating between cellular and misfolded prion protein by using affinity to 9-aminoacridine compounds. *J. Gen. Virol.* 88, 1392–1401.
- Prusiner, S.B., Scott, M.R., DeArmond, S.J., Cohen, F.E., 1998. Prion protein biology. *Cell* 93, 337–348.
- Rhie, A., Kirby, L., Sayer, N., Wellesley, R., Disterer, P., Sylvester, I., Gill, A., Hope, J., James, W., Tahiri-Alaoui, A., 2003. Characterization of 2'-fluoro-RNA aptamers that bind preferentially to disease-associated conformations of prion protein and inhibit conversion. *J. Biol. Chem.* 278, 39697–39705.
- Safar, J., Roller, P.P., Gajdusek, D.C., Gibbs Jr., C.J., 1993. Conformational transitions, dissociation, and unfolding of scrapie amyloid (prion) protein. *J. Biol. Chem.* 268, 20276–20284.
- Safar, J., Roller, P.P., Gajdusek, D.C., Gibbs Jr., C.J., 1994. Scrapie amyloid (prion) protein has the conformational characteristics of an aggregated molten globule folding intermediate. *Biochemistry* 33, 8375–8383.
- Safar, J., Wille, H., Itri, V., Groth, D., Serban, H., Torchia, M., Cohen, F.E., Prusiner, S.B., 1998. Eight prion strains have PrP(Sc) molecules with different conformations. *Nat. Med.* 4, 1157–1165.
- Safar, J.G., Geschwind, M.D., Deering, C., Didorenko, S., Sattavat, M., Sanchez, H., Serban, A., Vey, M., Baron, H., Giles, K., Miller, B.L., Dearmond, S.J., Prusiner, S.B., 2005. Diagnosis of human prion disease. *Proc. Natl. Acad. Sci. U.S.A.* 102, 3501–3506.
- Serban, D., Taraboulos, A., DeArmond, S.J., Prusiner, S.B., 1990. Rapid detection of Creutzfeldt-Jakob disease and scrapie prion proteins. *Neurology* 40, 110–117.
- Shindoh, R., Kim, C.L., Song, C.H., Hasebe, R., Horiuchi, M., 2009. The region approximately between amino acids 81 and 137 of proteinase K-resistant PrP^{Sc} is critical for the infectivity of the chandler prion strain. *J. Virol.* 83, 3852–3860.
- Sigurdson, C.J., Nilsson, K.P., Hornemann, S., Manco, G., Polymenidou, M., Schwarz, P., Leclerc, M., Hammarström, P., Wüthrich, K., Aguzzi, A., 2007. Prion strain discrimination using luminescent conjugated polymers. *Nat. Methods* 4, 1023–1030.
- Silveira, J.R., Raymond, G.J., Hughson, A.G., Race, R.E., Sim, V.L., Hayes, S.F., Caughey, B., 2005. The most infectious prion protein peptides. *Nature* 437, 257–261.
- Sklaviadis, T., Akowitz, A., Manuelidis, E.E., Manuelidis, L., 1993. Nucleic acid binding proteins in highly purified Creutzfeldt-Jakob disease preparations. *Proc. Natl. Acad. Sci. U.S.A.* 90, 5713–5717.
- Snow, A.D., Kisilevsky, R., Willmer, J., Prusiner, S.B., DeArmond, S.J., 1989. Sulfated glycosaminoglycans in amyloid plaques of prion diseases. *Acta Neuropathol.* 77, 337–342.
- Solfrosi, L., Bellon, A., Schaller, M., Cruite, J.T., Abalos, G.C., Williamson, R.A., 2007. Toward molecular dissection of PrP^C-PrP^{Sc} interactions. *J. Biol. Chem.* 282, 7465–7471.
- Ulrih, N.P., Skrt, M., Veranic, P., Galvani, V., Vranac, T., Curin Serbec, V., 2006. Oligomeric forms of peptide fragment PrP(214–226) in solution are preferentially recognized by PrP(Sc)-specific antibody. *Biochem. Biophys. Res. Commun.* 344, 1320–1326.
- Taraboulos, A., Jendroska, K., Serban, D., Yang, S.L., DeArmond, S.J., Prusiner, S.B., 1992. Regional mapping of prion proteins in brain. *Proc. Natl. Acad. Sci. U.S.A.* 89, 7620–7624.
- Williamson, R.A., Peretz, D., Smorodinsky, N., Bastidas, R., Serban, H., Mehlhorn, I., DeArmond, S.J., Prusiner, S.B., Burton, D.R., 1996. Circumventing tolerance to generate autologous monoclonal antibodies to the prion protein. *Proc. Natl. Acad. Sci. U.S.A.* 93, 7279–7282.

